Methyl 2-aminooxazole-4-carboxylate (CAS 1000576-38-4), also named methyl 2-amino-1,3-oxazole-4-carboxylate, is a small heterocyclic building block with the molecular formula C₅H₆N₂O₃ and a molecular weight of 142.11. It presents as a crystalline solid and carries two orthogonal handles on a single oxazole ring: an amino group at the 2-position and a methyl ester at the 4-position. That arrangement is the molecule’s entire commercial rationale. The amino group supports acylation, alkylation and amide-bond formation, while the ester provides a point of hydrolysis, transesterification or conversion to an amide or ketone. In medicinal chemistry, this bifunctionality allows the oxazole core to be elaborated in two independent directions without protecting-group gymnastics, which is why the compound is used as an intermediate for pharmaceuticals targeting enzyme inhibition or receptor modulation. The most commercially significant application sits within targeted protein degradation. Methyl 2-aminooxazole-4-carboxylate is catalogued explicitly as a “Protein Degrader Building Block,” positioning it in the PROTAC (proteolysis-targeting chimera) and molecular-glue supply chain, where heterocyclic linkers and warheads are assembled from precisely functionalized fragments. The market for this building block is not measured in kilotonnes and is unlikely to be. It is a research-to-process specialty chemical whose value is determined by the scarcity of reproducible, analytically clean material that medicinal and process chemists can trust in structure-activity relationship campaigns and scale-up. Published pricing illustrates the grade and package spread: 1 g at £25, 5 g at £56, 25 g at £185 and 100 g at £719 from one UK-based supplier, with Chinese stock availability at 5+ units for the smaller pack sizes. The commercial question for buyers is therefore not “what does a tonne cost” but “which supplier can deliver a lot that matches the Certificate of Analysis, when the SAR clock is running.”
Core Application Fields and Demand Architecture
Demand for methyl 2-aminooxazole-4-carboxylate concentrates in three functional arenas where the 2-amino-4-carboxylate substitution pattern on the oxazole ring is specifically useful: targeted protein degradation, kinase and enzyme inhibitor discovery, and custom synthesis and scale-up services.
In targeted protein degradation, the compound functions as a heterocyclic building block for PROTAC linkers and degrader warheads. PROTACs are bifunctional molecules that recruit an E3 ligase on one end and bind a target protein on the other; the linker chemistry between the two ligands determines ternary-complex geometry, degradation efficiency and drug-like properties. Oxazole-containing fragments offer rigidity, hydrogen-bonding capacity and metabolic stability that purely aliphatic linkers cannot provide, and the 2-amino-4-carboxylate pattern allows the fragment to be incorporated with defined vectors for both the linker and the target-binding or ligase-binding moiety. The commercial significance is indirect but real: as PROTAC programs move from tool compounds to development candidates, the demand for well-characterized heterocyclic building blocks with documented purity and lot-to-lot consistency increases, because the degrader’s synthesis must be reproducible at scale. Suppliers that catalogue the compound as a dedicated protein-degrader building block, rather than as a generic heterocycle, are signalling that they understand the application and can support the analytical expectations that come with it.
In kinase and enzyme inhibitor discovery, the oxazole core appears in medicinal chemistry campaigns as a bioisostere for other five-membered heterocycles and as a scaffold for ATP-competitive and allosteric inhibitors. The 2-amino group can engage in hinge-region hydrogen bonding, while the 4-carboxylate provides a handle for appending solubilizing groups or for conversion to amides that modulate potency and selectivity. The compound’s value in this segment is as a versatile intermediate rather than as a final active pharmaceutical ingredient, and demand tracks the intensity of medicinal chemistry screening rather than the commercial success of any single drug. This makes the demand base fragmented and project-driven: a single PROTAC or kinase program can consume grams to hundreds of grams over its lifetime, and the aggregate demand across many programs is what sustains the commercial supply.
Custom synthesis and scale-up services form the third arena. Suppliers list methyl 2-aminooxazole-4-carboxylate as an intermediate for custom synthesis, route development and scale-up, reflecting the reality that many buyers need not just the catalogue item but a partner who can produce larger quantities under a defined specification and provide the analytical and regulatory documentation that process chemistry requires. This service dimension is commercially important because the compound is rarely available in tonnage quantities from stock, and a program that advances from hit to lead to candidate will need a supply route that scales with it.
Regulatory Profile: A Research-Scale Heterocycle with an Unlisted TSCA Status and a Sensitization-Relevant Hazard Profile
Methyl 2-aminooxazole-4-carboxylate is not a high-production-volume industrial chemical, and its regulatory profile reflects that: the operative constraints are workplace handling, irritancy classification and, critically for U.S.-facing buyers, the fact that it is not listed on the TSCA Inventory.
The TSCA status is the single most consequential regulatory fact for this compound. One supplier’s product data explicitly records “TSCA收录: false”. For a substance not on the TSCA Inventory, manufacture or import into the United States for commercial purposes would ordinarily require a Premanufacture Notice (PMN) or an applicable exemption, most commonly the R&D exemption under 40 CFR 720.36 for research and development quantities used by or directly under the supervision of a technically qualified individual. This means the compound’s U.S. commercial pathway is currently structured around research-scale supply, not around commodity import. Buyers in the United States who intend to use the material in process development must confirm that their supplier’s TSCA position supports the intended use, and suppliers that can document R&D-exempt status or provide a PMN pathway add value that a generic catalogue listing does not.
The hazard profile is that of a solid irritant rather than a CMR substance. The safety data sheet reports GHS07 (Harmful/Irritant) with signal word “Warning” and hazard statements H315 (causes skin irritation), H319 (causes serious eye irritation) and H335 (may cause respiratory irritation). These are handling hazards, not carcinogenicity, mutagenicity or reproductive toxicity classifications, and the compound is not reported as an SVHC. That distinction matters for pharmaceutical process use: an irritant building block can be managed with engineering controls and PPE, whereas a CMR classification would trigger far stricter containment and residue limits in the final API. The required precautions are standard for a fine chemical solid—avoid breathing dust, wear protective gloves and eye protection, use in a well-ventilated area, and store the container tightly closed.
In the European Union, the compound falls outside the scope of REACH registration if manufactured or imported below one tonne per annum, and no SVHC listing applies. Downstream pharmaceutical users will still require a safety data sheet and, for process use, an assessment of residual solvent and elemental impurity profiles against ICH Q3C and Q3D expectations. For Russian and EAEU buyers, the compound is imported at research and pilot scale, with documentation expectations centered on a Certificate of Analysis, a Russian-language SDS, and confirmation of identity and purity by NMR and HPLC. Because the material is supplied at 95–98% purity across different vendors, the buyer’s incoming QC must be capable of distinguishing a specification-compliant lot from a nominal-grade lot that does not meet the program’s needs.
Global Supply Structure and Manufacturer Differentiation
Global supply of methyl 2-aminooxazole-4-carboxylate is fragmented and research-oriented. The supplier landscape includes catalogue and research-chemical companies alongside custom-synthesis houses and Chinese producers, with no single dominant manufacturer exercising the kind of capacity control seen in commodity heterocycles.
The suppliers visible in public listings span Fluorochem, Matrix Scientific, AKSci, ChemScene, Adamas, MolCore, TargetMol, Capot Chemical, MuseChem, EvitaChem and a cohort of Chinese custom-synthesis providers. This fragmentation is typical of a building block at the pre-commercial stage: the molecule is made in batch quantities, often against projected demand or as part of a broader heterocycle portfolio, and availability is measured in grams to hundreds of grams rather than in tonnes. Purity specifications range from 95% to 98% depending on the supplier and the analytical method used, and some suppliers report lot-specific NMR, HPLC and GC data while others offer only a nominal purity figure. For a medicinal chemist, the difference between a 95% lot and a 98% lot can determine whether a reaction delivers a clean product or requires chromatographic purification, and the certificate of analysis is the only reliable way to know which one is being purchased.
Differentiation operates on three axes. The first is analytical depth and lot-specific data. Suppliers that provide NMR, HPLC and GC results for the specific lot, rather than a generic specification, reduce the buyer’s need to re-characterize material before use. In PROTAC and kinase programs, where the building block is incorporated into a complex molecule and purification is expensive, the cost of an off-spec lot is measured in lost synthesis time rather than in the price of the gram. The second axis is scale-up and custom-synthesis capability. Many projects begin with a 1 g catalogue purchase and later require 100 g or kilogram quantities under a locked specification. A supplier that can follow the program from catalogue scale to custom scale, without changing the analytical method or the impurity profile, is more valuable than a catalogue vendor that cannot support the later stage. The third axis is documentation and regulatory support. For U.S.-facing programs, the TSCA-unlisted status means the supplier must be able to clarify the R&D-exempt basis for shipment; for EU and EAEU buyers, a Russian-language SDS and a complete Certificate of Analysis are baseline expectations. In a fragmented market where the molecule is the same but the qualification burden varies by destination, documentation and scale-up capability are genuine differentiators.
Regional Demand Dynamics
Demand for methyl 2-aminooxazole-4-carboxylate follows the geography of medicinal chemistry and biotech R&D rather than the geography of chemical manufacturing.
North America and Europe are the principal demand centers, reflecting the concentration of PROTAC and targeted-protein-degradation research, kinase inhibitor discovery and contract research organizations in these regions. Demand is project-driven and small in absolute mass: a single medicinal chemistry group may purchase grams at a time, and a program that advances may require tens to hundreds of grams. The U.S. market carries the additional TSCA consideration described above, which tends to keep commercial flows at research scale unless a PMN or exemption pathway is established. European demand is similarly research-intensive, with buyers placing weight on supplier documentation, analytical data and the ability to support custom synthesis as programs progress.
Asia-Pacific, and China in particular, is the manufacturing and stock-holding hub for the compound. Many catalogue suppliers maintain Chinese stock, and Chinese custom-synthesis houses offer the building block alongside route development and scale-up services. The region’s demand is growing as domestic drug-discovery and PROTAC research expands, and Chinese suppliers are increasingly capable of providing 98% material with lot-specific analytical data. For Russian and EAEU buyers, China is the most accessible source of supply, with the practical qualification task centered on verifying the Certificate of Analysis and the SDS rather than on navigating a complex regulatory approval pathway.
Russia and the EAEU form a small, import-dependent contour. Demand comes from pharmaceutical R&D, medicinal chemistry groups and custom-synthesis service providers, and supply is sourced from Chinese and European catalogue vendors. There is no meaningful domestic production of the compound, and the practical constraint is availability at the required purity and package size rather than regulatory restriction. Buyers in the region place a premium on suppliers that can provide a Russian-language SDS, a lot-specific Certificate of Analysis and reliable delivery of small packages, because a delayed gram can stall a synthesis campaign.
Future Outlook and Strategic Imperatives
The commercial trajectory of methyl 2-aminooxazole-4-carboxylate is tied less to its own market size than to the fortunes of the therapeutic modalities it enables. Targeted protein degradation is one of the most active areas in drug discovery, and as PROTAC and molecular-glue programs advance from tool compounds toward clinical candidates, the demand for well-characterized heterocyclic building blocks with reproducible specifications will increase. Kinase inhibitor discovery provides a second, steadier demand stream, and custom synthesis for process development adds a service layer that grows with every program that chooses the oxazole scaffold.
Three structural forces will shape the supply landscape. First, the transition from catalogue to custom scale will separate suppliers that can support a program’s growth from those that can only fill a gram order. A supplier that can lock a specification at 1 g and reproduce it at 100 g or 1 kg, with the same impurity profile and analytical method, will be preferred for process development, because re-qualification of a building block mid-program is costly. Second, analytical transparency will become a baseline expectation. As PROTAC and kinase programs mature, the building block’s purity and impurity profile directly affect the purity of the final degrader or inhibitor, and buyers will increasingly require lot-specific NMR and HPLC data rather than a nominal percentage. Third, the TSCA-unlisted status will continue to shape U.S. market access. Suppliers that can clearly document the R&D-exempt basis for shipment, or that can support a PMN pathway for larger volumes, will be better positioned as U.S. programs advance beyond research scale.
For Russian and EAEU buyers, the strategic implication is that procurement should be treated as a specification-and-documentation decision rather than a price comparison. A nominal 95% lot that fails to meet the program’s purity requirement, or a shipment that arrives without a Russian-language SDS, can cost more in lost synthesis time than the price difference between two suppliers. The lowest-risk source is the one that can provide lot-specific analytical data, a clear statement of TSCA status for U.S.-linked programs, and the ability to scale the specification as the project advances.
Shanghai XinChem Co., Ltd. (XinChem)
As a world-leading supplier of organic chemicals, Shanghai XinChem Co., Ltd. (XinChem) offers methyl 2-aminooxazole-4-carboxylate (CAS 1000576-38-4) in research-grade and custom-synthesis specifications, serving medicinal chemistry groups, PROTAC and targeted-degradation programs, kinase inhibitor discovery teams and pharmaceutical process development organizations. Our material is supplied with lot-specific analytical data, controlled purity and the documentation support that building-block qualification requires at both catalogue and scale-up stages.
Technical and Quality Advantages
Lot-Specific Analytical Data: Methyl 2-aminooxazole-4-carboxylate is supplied with a Certificate of Analysis reporting identity and purity by NMR and HPLC for the specific lot, rather than a generic catalogue specification. For PROTAC and kinase programs, where the building block’s impurity profile affects downstream synthesis and purification, lot-level data allows the buyer to qualify the material against the program’s actual requirements.
Purity Control at the 98% Threshold: Material is available at ≥98% purity (HPLC), with lower-grade material available for applications where a 95% specification is sufficient. The explicit grade distinction allows medicinal chemists to select the specification that matches their synthetic route, rather than discovering after purchase that a nominal-grade lot requires additional purification.
Custom Synthesis and Scale-Up Pathway: The compound is available from gram-scale research quantities through to custom-synthesis batches under a locked specification. A program that begins with a 1 g qualification lot can later scale to 100 g or larger quantities without changing the analytical method or the impurity profile, reducing the re-qualification burden that arises when a catalogue vendor cannot follow the program.
Regulatory and Documentation Support: Safety data sheets are available in English and Russian, with documentation covering the GHS07 irritant classification (H315, H319, H335) and the current TSCA-unlisted status. For U.S.-facing programs, XinChem provides clarity on the R&D-exempt basis for shipment, and for EAEU buyers the Russian-language SDS and Certificate of Analysis support incoming qualification.
Packaging and Logistics Flexibility
Methyl 2-aminooxazole-4-carboxylate is available in sealed 1 g, 5 g and 25 g containers for research and medicinal chemistry use, and in larger package sizes for custom-synthesis and process-development quantities. For Russia and EAEU destinations, XinChem arranges logistics with appropriate customs and transport documentation, including Russian-language SDS and Certificate-of-Analysis support, to reduce clearance friction for a building block that is sourced internationally at research scale.
Application Support and Supply Reliability
XinChem’s technical team assists with grade selection for PROTAC linker and warhead synthesis, kinase inhibitor discovery and custom-synthesis route development, and with the analytical and documentation requirements that building-block qualification demands. Supply schedules accommodate both catalogue-scale qualification orders and custom-synthesis volumes, with stock held for the package sizes most commonly requested in medicinal chemistry programs.
Why Choose XinChem
Expertise: Deep experience in heterocyclic building blocks and pharmaceutical intermediates, with application knowledge spanning targeted protein degradation, kinase inhibitor discovery and custom synthesis.
Consistency: Lot-specific control of identity and purity by NMR and HPLC—the parameters that determine whether the building block incorporates cleanly into a complex molecule or introduces a purification burden.
Compliance Readiness: Documentation structured around the GHS07 irritant classification, the current TSCA-unlisted status and EAEU documentation expectations, with Russian-language SDS support.
Responsiveness: Direct technical and commercial access, with order structures from gram-scale qualification to custom-synthesis quantities.
Contact us now to discuss your methyl 2-aminooxazole-4-carboxylate requirements and request a specification sheet or qualification sample.
Website: www.xinchem.com
Email: sales1@xinchem.com
WhatsApp: +86 18049800532
Post time: Oct-28-2026